All in the head: obstacles for immune rejection of brain tumours.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023
   Review
2. Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma.Neuro-oncology · 2021
   Article
3. Function of PD-L1 in antitumor immunity of glioma cells.Saudi journal of biological sciences · 2017
   Article
4. Impact of Human Immunodeficiency Virus in the Pathogenesis and Outcome of Patients with Glioblastoma Multiforme.Brain tumor research and treatment · 2016
   Article
5. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.PloS one · 2016
   Article
6. Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept.Journal of therapeutic ultrasound · 2016
   Review
7. Transforming growth factor-beta and its implication in the malignancy of gliomas.Targeted oncology · 2015
   Review
8. Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling.Molecular and cellular biology · 2013
   Article
9. Targeting brain metastases in patients with melanoma.BioMed research international · 2013
   Review
10. Prediagnostic plasma IgE levels and risk of adult glioma in four prospective cohort studies.Journal of the National Cancer Institute · 2011
    Article
11. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Seminars in immunology · 2010
    Review
12. Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper.Journal of neuro-oncology · 2010
    Review
13. Immunotherapy of brain cancers: the past, the present, and future directions.Clinical & developmental immunology · 2010
    Review
14. Immunotherapy of diffuse gliomas: biological background, current status and future developments.Brain pathology (Zurich, Switzerland) · 2009
    Review
15. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.Neuro-oncology · 2009
    Article
16. Gammadelta T cells as immune effectors against high-grade gliomas.Immunologic research · 2009
    Review
17. Immunotherapeutic approaches for glioma.Critical reviews in immunology · 2009
    Review
18. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.Cancer immunity · 2007
    Review
19. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.Cancer immunology, immunotherapy : CII · 2006
    Article
20. Mechanisms of malignant glioma immune resistance and sources of immunosuppression.Gene therapy & molecular biology · 2006
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as